Cellular consequences of the association of apoB lipoproteins with proteoglycans: Potential contribution to atherogenesis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 6, 1997, Pages 1011-1017

  Hurt Camejo, Eva ^a   Olsson, Urban ^a   Wiklund, Olov ^a   Bondjers, Göran ^a   Camejo, Germán ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

apoB lipoproteins; Atherogenesis; Proteoglycan

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PROTEOGLYCAN; VERY LOW DENSITY LIPOPROTEIN;

ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; HUMAN; INTIMA; LIPOPROTEIN METABOLISM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0030947630     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.6.1011     Document Type: Short Survey

References (101)

1. Group SSSS. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. Shepherd J, Cobbe S, Ford I, Isles C, Lorimer R, MacFarlane P, McKillo'p J, Packard C. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-1307.
3. Sacks F, Pfeffer M, Moyer L, Rouleau J, Rutherford J, Cole T, Brown L, Warnica J, Arnold J, Wun C-C, Davis B, Brauwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335: 1001-1009.
4. Faber M. The human aorta: sulfate-containing polyuronides and the deposition of cholesterol. Arch Palhol. 1949;48:342-350.
5. Wight TN. The vascular extracellular matrix. In: Fuster V, Ross R, Topol E, eds. Atherosclerosis and Coronary Artery Disease, I. Philadelphia, Pa: Lippincott-Raven Publishers; 1996:421-440.
6. Walton K, Williamson N. Histological and immunofluorescent studies on the evolution of the human atheromatous plaque. J Atheroscler Res. 1968;8:599-624.
7. Hoff H, Bond G. Apolipoprotein B localization in coronary atherosclerotic plaques from cynomolgus monkeys. Artery. 1983;12:104-116.
8. Hollander W. Unified concept on the role of acidic mucopolysaccharides and connective tissue proteins in the accumulation of lipids, lipoproteins, and calcium in the atherosclerotic plaque. Exp Mol Pathol. 1976:25:106-120.
9. Smith EB, Slater R. Lipids and low density lipoproteins in intima in relation to its morphological characteristics. Ciba Symp. 1973;12:39-62.
10. Hoff HF, Gaubatz JW. Isolation, purification and characterization of a lipoprotein containing apo B from the human aorta. Atherosclerosis. 1982;42:273-297.
11. Camejo G, Hurt E, Romano M. Properties of lipoprotein complexes isolated by affinity chromatography from human aorta. Blamed Biochim Acta. 1985;44:389-401.
12. Daugherty A, Zweifel BS, Sobel BE, Schonfeld G. Isolation of low density lipoprotein from atherosclerotic vascular tissue of Watanabe heritable hyperlipidemic rabbits. Arteriosclerosis. 1988;8: 768-777.
13. Tailleux A, Torpier G, Caron B, Fruchart J-C, Fievet C. Immunological properties of apoB-containing lipoprotein particles in human atherosclerotic arteries. J Lipid Res. 1993;34:719-728.
14. Rapp J, Lespine A, Hamilton R, Colyvas N, Chaumeton A, Tweedie-Hardman J, Kotite L, Kunitake T, Havel R, Kane J. Triglyceride-rich lipoproteins isolated by selected-affinity antiapolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb. 1994;14:1767-1774.
15. 125I-tyramine cellobiose-LDL in atherosclerotic lesions of the WHHL rabbit. Arterioscler Thromb. 1992;12:985-995.
16. Nievelstein-Post P, Mottino G, Fogelman A, Frank J. An ultrastructural study of lipoprotein accumulation in cardiac valves of the rabbit. Arterioscler Thromb. 1994;14:1151-1161.
17. Galis Z, Alavi M, Moore S. Colocalization of aortic apolipoprotein B and chondroitin sulfate in an injury model of atherosclerosis. Am J Palhol. 1993;142:1432-1438.
18. Adams CW. Tissue changes and lipid entry in developing atheroma. Ciba Symp. 1973;12:30-38.
19. Guyton JR, Klemp KF. Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol. 1996; 16:4-11.
20. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
21. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vase Biol. 1995;15: 551-561.
22. Bernfeld P, Nisselbaum J. Reaction of human betalipoglobulin with macromolecular polysulfated esters. Fed Proc. 1956;15:220-227.
23. Gero S, Gergely J, Szérely L, Virag S. Role of mucoid substances of the aorta in the deposition of lipids. Nature. 1960;187:152-153.
24. Bihari-Varga M, Vegh M. Quantitative studies on the complexes formed between aortic mucopolysaccharides and serum lipoproteins. Biochim Biophys Acta 1967:144:202-210.
25. Iverius P-H. The interaction between human plasma lipoproteins and connective tissue glycosaminoglycans. J Biol Chem. 1972;247: 2607-2613.
26. Avila EM, López F, Camejo G. Properties of low density lipoproteins related to its interaction with arterial wall components: in vitro and in vivo studies. Artery. 1978;4:36-60.
27. Camejo G, López A, López F, Quińones J. Interaction of low density lipoproteins with arterial proteoglycans: the role of charge and sialic acid content. Atherosclerosis. 1985;55:93-105.
28. Camejo G, Linden T, Olsson U, Wiklund O, López F, Bondjers G. Binding parameters and concentration modulate formation of complexes between LDL and arterial proteoglycans in serum. Atherosclerosis. 1989;79:121-128.
29. Weisgraber KH, Rall SJ. Human apolipoprotein B-100 heparinbinding sites. J Biol Chem. 1987;262:11097-11103.
30. Hirose N, Blankenship DT, Krivanek MA, Jackson RL, Cardin AD. Isolation and characterization of four heparin-binding cyanogen bromide peptides of human plasma apolipoprotein B. Biochemistry. 1987;26:5505-5512.
31. Chan L. Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins. J Biol Chem. 1992;267: 25621-25624.
32. Camejo G, Olofsson S-O, López F, Carlsson P, Bondjers G. Identification of apoB-100 segments mediating the interaction of low density lipoproteins with arterial proteoglycans. Arteriosclerosis. 1988;8:368-377.
33. Cardin A, Jackson R, Sparrow J. Interaction of glycosaminoglycans with lipoproteins. Ann N Y Acad Sci. 1989;556:186-193.
34. Olsson U, Camejo G, Olofsson S-O, Bondjers G. Molecular parameters that control the association of low density lipoprotein apoB-100 with chondroitin sulphate. Biochim Biophys Acta 1991:1097: 37-44.
35. Jackson RL, Busch SJ, Cardin AD. Glycosaminoglycans: molecular properties, protein interactions and role in physiological processes. Physiol Rev. 1991;71:481-539.
36. Olsson U, Camejo G, Bondjers G. Binding of a synthetic apolipoprotein B-100 peptide and peptide analogues to chondroitin 6-sulfate: effects of the lipid environment. Biochemistry. 1993;32: 1858-1865.
37. Olsson U, Camejo G, Hurt-Camejo E, Elfsber K, Wiklund O, Bondjers G. Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the apoB/E receptor. Arterioscler Thromb Vase Biol. 1997:17:149-155.
38. Hurt-Camejo E, Camejo G, Rosengren B, López F, Wiklund O, Bondjers G. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res. 1990;31:1387-1398.
39. Wagner WD, Salisbury EG, Rowe HA. A proposed structure of chondroitin 6-sulfate proteoglycans of human normal and adjacent atherosclerotic plaque. Arteriosclerosis. 1988;6:407-417.
40. Radhakrishnamurthy B, Srinivasan S, Vijayagopal P, Berenson G. Arterial wall proteoglycans: biological properties related to pathogenesis of atherosclerosis. Eur Heart J. 1990;11(suppl E): 148-157.
41. Wasty F, Alavi MZ, Moore S. Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetologia. 1993;36:316-322.
42. Ismail NA, Alavi M, Moore S. Lipoprotein-proteoglycan complexes from injured rabbit aortas accelerate lipoprotein uptake by arterial smooth muscle cells. Atherosclerosis. 1994;105:79-87.
43. Steele R, Wagner W. Lipoprotein interaction with artery wall derived proteoglycan: comparison between atherosclerosis-susceptible WC-2 and resistant Show Racer pigeons. Atherosclerosis. 1987;65:63-73.
44. Hoff H, Wagner W. Plasma low density lipoprotein accumulation in aortas of hypercholesterolemic swine correlates with modification of aortic glycosaminoglycan composition. Atherosclerosis. 1986; 61:231-236.
45. Cardoso LE, Mourao PA. Glycosaminoglycan fractions from human arteries presenting diverse susceptibilities to atherosclerosis have different binding affinities to plasma LDL. Arterioscler Thromb. 1994;14:115-124.
46. Merriles MJ, Campbell JH, Spanidis E, Campbell OR. Glycosaminoglycan synthesis by smooth muscle cells of differing phenotype and their response to endothelial cell conditioned media. Atherosclerosis. 1990;81:245-254.
47. Schönherr E, Järveläinen HT, Sandell LJ, Wight TN. Effects of platelet-derived growth factor and transforming growth factor-β1 on the synthesis of large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cell. J Dial Chem. 1991;266: 17640-17647.
48. Camejo G, Fager G, Rosengren B, Camejo-Hurt E, Bondjers G. Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J Biol Chem. 1993;268:I4131-14137.
49. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits, I: focal increases in arterial LDL concentrations precede development of fatty streak lesions. Arteriosclerosis. 1989;9:895-907.
50. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol fed rabbits, II: selective retention of LDL versus selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis. 1989;9:908-918.
51. Schwenke D. Selective increase in cholesterol at atherosclerosissusceptible aortic sites after short-term cholesterol feeding. Arterioscler Thromb Vase Biol. 1995:15:1928-1937.
52. Björnheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis. 1996;123: 43-56.
53. Nielsen LB, Slender S, Jauhiainen M, Nordestgaard BG. Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with nonlesioned rabbit aorta. J Clin Invest. 1996;98:563-571.
54. Kovanen PT. Mast cell granule-mediated uptake of low density lipoproteins by macrophages: a novel carrier mechanism leading to formation of foam cells. Ann Med. 1991;23:551-559.
55. Wang Y, Lindstedt KA, Kovanen PT. Mast cell granule remnants carry LDL into smooth muscle cells of the synthetic phenotype and induce their conversion into foam cells. Arterioscler Thromb Vase Biol. 1995;15:801-810.
56. Owens RT, Wagner WD. Proteoglycans produced by cholesterolenriched macrophages bind plasma low density lipoproteins. Atherosclerosis. 1991:91:229-240.
57. Edwards IJ, Xu H, Obunike JC, Goldberg IJ, Wagner WD. Differentiated macrophages synthesize a heparan sulfate proteoglycan and an oversulfated chondroitin sulfate proteoglycan that bind lipoprotein lipase. Arterioscler Thromb Vase Biol. 1995;15: 400-409.
58. Saxena U, Klein MG, Vanni T, Goldberg IJ. Lipoprotein lipase increases low density lipoprotein retention by subendothelial cell matrix. J Clin Invest. 1992;89:373-380.
59. Eisenberg S, Sehayek E, Olivecrona T, VIodavsky I. Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. J Clin Invest. 1992:90:2013-2021.
60. Williams KJ, Fless GM, Petrie KA, Snyder ML, Brocia RW, Swenson TL. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins: roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J Biol Chem. 1992;267:13284-13292.
61. Saxena U, Auerbach BJ, Ferguson E, Wölle J, Marcel YL, Weisgraber KH, Hegele RA, Bisgaier CL. Apolipoprotein B and E basic amino acid clusters influence low-density lipoprotein association with lipoprotein lipase anchored to the subendothelial matrix. Arterioscler Thromb Vasc Biol. 1995:15:1240-1247.
62. Fernandez-Borja M, Bellido D, Vilella E, Olivecrona G, Vilaró S. Lipoprotein lipase mediated uptake of lipoprotein in human fibroblasts: evidence for an LDL receptor-independent internalization pathway. J Lipid Res. 1996:37:464-481.
63. Goldberg I. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res. 1996:37:693-707.
64. Hurt E, Bondjers G, Camejo G. Interaction of LDL with human arterial proteoglycans stimulates its uptake by human monocytederived macrophages. J Lipid Res. 1990:31:443-454.
65. Mateu L, Avila EM, León V, Liscano N. The structural stability of low density lipoprotein: a kinetic x-ray scattering study of its interaction with arterial wall proteoglycans. Biochim Biophys Acta 1984:795:525-534.
66. Camejo G, Hurt E, Wiklund O, Rosengren B, López F, Bondjers G. Modifications of low density lipoprotein induced by arterial proteoglycans and chondroitin-6-sulfate. Biochim Biophys Acta 1991; 1096:253-261.
67. Ylä-Herttuala S. Macrophages and oxidized low density lipoproteins in the pathogenesis of atherosclerosis. Ann Med. 1991;23:561-567.
68. Hoff H, O'Neil J. Lesion-derived low density lipoprotein and oxidized low density lipoprotein share a lability for aggregation leading to enhanced macrophage degradation. Arterioscler Thromb. 1991:11:1209-1222.
69. Jurgens G, Chen Q, Esterbauer H, Mair S, Ledinski G, Dinges HP. Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apolipoprotein(a). Arterioscler Thromb. 1993:13:1689-1699.
70. Berliner J, Heinecke J. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996;20:707-727.
71. Navab M, Berliner J, Watson AD, Hama SS, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM. The yin and yang of oxidation in the development of the fatty streak. Arterioscler Thromb Vase Biol. 1996;16:831-842.
72. Camejo G, Hurt-Camejo E, Rosengren B, Wiklund O, López F, Bondjers G. Modification of copper-catalyzed oxidation of low density lipoprotein by proteoglycans and glycosaminoglycans. J Lipid Res. 1991:32:1983-1991.
73. Sutherland WH. Oxidation of heparin isolated LDL by hemin: the effect of serum components. Arterioscler Thromb. 1994;14: 1966-1975.
74. Hurt-Camejo E, Camejo G, Rosengren B, López F, Ahlström C, Fager G, Bondjers G. Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arterioscler Thromb. 1992:12:569-583.
75. Tribble D, Krauss RM, Langsberg M, Thiel PM, van den Berg J. Greater oxidative susceptibility of the surface monolayer in small dense LDL may contribute to differences in copper-induced oxidation among LDL subfractions. J Lipid Res. 1995:36:662-671.
76. Srinivasan SR, Yost C, Bhandaru RR, Radahkrisnamurthy B, Berenson GS. Lipoprotein-glycosaminoglycan interactions in aortas of rabbits fed atherogenic diets containing different fats. Atherosclerosis. 1982:43:289-301.
77. Vijayagopal P, Srinivasan SR, Radhakrishnamurthy B, Berenson GS. Lipoprotein-proteoglycan complexes from atherosclerotic lesions promote cholesteryl ester accumulation in human monocytes/macrophages. Arterioscler Thromb. 1992;12:237-249.
78. Camejo G, LaLaguna F, López F, Starosta R. Characterization and properties of a lipoprotein-complexing proteoglycan from human aorta. Atherosclerosis. 1980;35:307-320.
79. Sartipy P, Johansen B, Camejo G, Rosengren B, Bondjers G, Hurt-Camejo E. Binding of human phospholipase A2 type II to proteoglycans: differential effect of glycosaminoglycans on enzyme activity. J Biol Chem. 1996:42:26307-26314.
80. Hurt-Camejo E, Andersen S, Sandal R, Rosengren B, Sartipy P, Stadberg E, Johansen B. Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries: activity of the isolated enzyme on low density lipoproteins. Arterioscler Thromb Vase Biol. 1997. In press.
81. Kume N, Gimbrone MA. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest. 1994:93:907-911.
82. Freeman J, Kuo W, Drenger B, Bamett T, Levine M, Flavahan N. Analysis of lysophosphatidylcholine-induced endothelial dysfunction. J Cardiovasc Pharmacol. 1996:28:345-352.
83. Chai Y, Howe P, DiCorleto P, Chisolm G. Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cell. J Biol Chem. 1996;271:1791-1797.
84. Schissel S, Tweedie-Hardman J, Rapp J, Graham G, Williams K, Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. J Clin Invest. 1996;98:1455-1464.
85. Hurt E, Camejo G. Effect of arterial proteoglycans on the interaction of LDL with human monocyte-derived macrophages. Atherosclerosis. 1987;67:115-126.
86. Bondjers G, Wiklund O, Fager G, Hurt E, Olofsson S-O, Camejo G. Low density lipoprotein interaction with arterial proteoglycans: effects on lipoprotein interaction with arterial cells. In: Sukling K, Groot P, eds. Hyperlipidemia and Atherosclerosis. London, UK: Academic Press; 1988:135-148.
87. McNamara J, Small D, Li Z, Schaefer E. Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B. J Lipid Res. 1996;37:1924-1935.
88. Tribble D, van den Berg JM, Motchnik PA, Ames BN, Lewis DM, Chait A, Krauss RM. Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and a-tocopherol content. Proc Natl Acad Sci U S A. 1994;91:1183-1187.
89. Vijayagopal P. Regulation of the metabolism of lipoprotein-proteoglycan complexes in human monocyte derived macrophages. Biochem J. 1994;301:675-681.
90. Vijayagopal P, Glancy L. Macrophages stimulate cholesteryl ester accumulation in cocultured smooth muscle cells incubated with lipoprotein-proteoglycan complex. Arterioscler Thromb Vase Biol. 1996;16:1112-1121.
91. Ji Z-S,. Sanan DA, Mahley RW. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J Lipid Res. 1995;36:583-592.
92. Stary HC. The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur Heart J. 1990;11:3-9.
93. Camejo G, Waich S, Quintero G, Berrizbeitia ML, LaLaguna F. The affinity of low density lipoproteins for an arterial macromolecular complex: a study in ischemic heart disease and controls. Atherosclerosis. 1976;24:341-354.
94. Camejo G, Acquatella H, LaLaguna F. The interaction of low density lipoproteins with arterial proteoglycans: an additional risk factor? Atherosclerosis. 1980;36:55-65.
95. Lindén T, Bondjers G, Camejo G, Bergstrand R, Wilhelmsen L, Wiklund O. Affinity of LDL to a human arterial proteoglycan among male survivors of myocardial infarction. Eur J Clin Invest. 1989;19:38-44.
96. Camejo G, Waich S, Mateu L, Acquatella H, LaLaguna F, Quintero G, Berrizbeitia ML. Differences in the structure of plasma low density lipoproteins and their relationship to the extent of interaction with arterial wall components. Ann NY Acad Sci. 1976;275: 153-168.
97. Anber V, Packard CJ, Sheperd J. Preferential binding of small, dense LDL to human arterial proteoglycan. Atherosclerosis. 1994; 109:217. Abstract.
98. Anber V, Griffin BA, McConnell M, Packard CJ, Sheperd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis. 1996; 124:261 -271.
99. Carmena R, Ascaso J, Camejo G, Varela G, Hurt-Camejo E, Ordovas J, Martinez-Valls J, Bergström M, Wallin B. Effect of olive and sunflower oils on low density lipoprotein level, composition, size, oxidation and interaction with arterial proteoglycans. Atherosclerosis. 1996:125:243-256.
100. Fagerberg B, Wiklund O, Agewall G, Camejo G, Wikstrand J. Multifactorial treatment of hypertensive men at high cardiovascular risk and low-density lipoprotein cholesterol affinity to human arterial proteoglycans. Eur J Clin Invest. 1996;26:960-965.
101. Wiklund O, Bondjers G, Wright I, Camejo G. Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effect of lipid lowering drugs. Atherosclerosis. 1996;119:57-68.